Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
November 02, 2023 09:09 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-weeks of continuous treatment from the third year...
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
October 31, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
October 30, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational...
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
October 25, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 (NT1) - ORX750 advancing in IND-enabling studies; Clinical...
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
October 03, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 31, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational...
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
August 23, 2023 17:08 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
August 14, 2023 07:00 ET
|
Centessa Pharmaceuticals plc
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment...
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
July 10, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, July 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 24, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational...